Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 3, 1995, Pages 195-202

  Baker, Sharyn D ^a   Heideman, Richard L ^a,b   Crom, William R ^a,b   Kuttesch, John F ^c   Gajjar, Amar ^a,b   Stewart, Clinton F ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CSF penetration; CSF pharmacokinetics; Topotecan

Indexed keywords

DRUG METABOLITE; TOPOTECAN;

ADOLESCENT; ARTICLE; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BAYES THEOREM; BRAIN NEOPLASMS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMAN; INFANT; INFUSIONS, INTRAVENOUS; MALE; STATISTICS, NONPARAMETRIC; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TOPOTECAN;

EID: 0029656180     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00688317     Document Type: Article

References (33)

1. Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys
2. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion
3. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates
4. Distribution in the cerebrospinal fluid and brain after intraventricular administration
5. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection
6. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability
7. Lipid bilayer partitioning and stability of camptothecin drugs
8. Topoisomerase I inhibitors: an overview of the camptothecin analogs
9. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro
10. Distributed model for drug delivery to CSF and brain tissue
11. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues
12. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts
13. Multicompartment models
14. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer
15. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly
16. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients
17. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa
18. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen
19. Phase I study of topotecan: a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia
20. Pharmacology of antineoplastic agents in cerebrospinal fluid
21. Camptothecins: from bench research to hospital wards
22. Phase I study of topotecan for pediatric patients with malignant solid tumors
23. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor
24. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor
25. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections
26. The current status of camptothecin analogues as antitumor agents
27. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity
28. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid
29. Equilibrium kinetics of the new experimental antitumor compound SK&F 104864-A in aqueous solution
30. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor
31. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days
32. Cytosine arabinoside cerebrospinal fluid kinetics